

Technology Advisory Committee C Interests Register

Topic [ID6327]

Publication Date: 19/06/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	TAC C Committee Member	Non-financial professional interest	Dr Ren provided statistical methodology consultancy service for Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis)	01/02/2024	It was agreed that Dr Ren's declaration would not prevent her from participating in discussions on this appraisal
Dr Steven Lloyd	TAC C Committee Member	Direct- financial	Dr Lloyd has done paid advisory work in the past for AbbVie in unrelated field. Dr Lloyd has also done paid advisory work with Pfizer in unrelated field namely Covid vaccinations and treatment, and paid advisory work with AbbVie in an unrelated field, namely immunology referral pathways	17/01/2024 06/02/2024	It was agreed that Dr Lloyd's declaration would not prevent him from participating in discussions on this appraisal
Satish Venkateshan	TAC C member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases including amyloidosis. Satish works for Regeneron,	22/01/2024	It was agreed that Satish's declaration would prevent him

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			pharmaceuticals/biotech company. Satish also owns shares in the company and has stock options.		from participating in discussions on this appraisal
Michael Chambers	TAC C member	Direct-financial	Michael is a member of an advisory panel for Pfizer (the submitting company), in an unrelated disease area (prostate cancer)	17/01/2024	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal
Professor Perry Elliott	Clinical expert	Direct- financial Non-financial professional interest	Professor Elliott has been on an advisory board and received speaker fees fir Pfizer and received unrestricted educational grant from Pfizer. Professor Elliott is the President of Cardiomyopathy UK and a trustee if International Cardiomyopathy Network.	15/09/2023	It was agreed that Professor Elliott's declaration would not prevent him from providing expert advice to the committee.
Professor Phillip Hawkins	Clinical expert	Direct- financial	Professor Hawkins has been an advisor for various pharmaceutical organisations.	02/11/2023	It was agreed that Professor Hawkins' declaration would not prevent him from providing expert advice to the committee